[go: up one dir, main page]

PA8604301A1 - Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades - Google Patents

Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades

Info

Publication number
PA8604301A1
PA8604301A1 PA20048604301A PA8604301A PA8604301A1 PA 8604301 A1 PA8604301 A1 PA 8604301A1 PA 20048604301 A PA20048604301 A PA 20048604301A PA 8604301 A PA8604301 A PA 8604301A PA 8604301 A1 PA8604301 A1 PA 8604301A1
Authority
PA
Panama
Prior art keywords
diseases
amino
treatment
pyridine derivatives
disorders
Prior art date
Application number
PA20048604301A
Other languages
English (en)
Inventor
Charlotte Alice Louise Lane
Alan Daniel Brown
Russell Andrew Lewthwaite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8604301A1 publication Critical patent/PA8604301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (1) Y A PROCEDIMIENTOS PARA PREPARAR, A INTERMEDIOS USADOS EN LA PREPARACION DE, A COMPOSICIONES QUE LOS CONTIENEN Y A LOS USOS DE DICHOS DERIVADOS. LOS COMPUESTOS DE ACUERFDO CON LA PRESENTE INVENCION SON UTILES EN NUMEROSAS ENFERMEDADES, TRASTORNOS Y AFECCIONES, EN PARTICULAR ENFERMEDADES, TRASTORNOS Y AFECCIONES INFLAMATORIAS, ALERGICAS Y RESPIRATORIAS.
PA20048604301A 2003-06-04 2004-06-03 Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades PA8604301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0312832.9A GB0312832D0 (en) 2003-06-04 2003-06-04 2-amino-pyridine derivatives useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
PA8604301A1 true PA8604301A1 (es) 2004-12-16

Family

ID=9959308

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048604301A PA8604301A1 (es) 2003-06-04 2004-06-03 Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades

Country Status (18)

Country Link
EP (1) EP1633715B1 (es)
JP (1) JP2006526613A (es)
AR (1) AR044475A1 (es)
AT (1) ATE372321T1 (es)
BR (1) BRPI0410946A (es)
CA (1) CA2527788A1 (es)
CL (1) CL2004001366A1 (es)
DE (1) DE602004008773T2 (es)
ES (1) ES2291882T3 (es)
GB (1) GB0312832D0 (es)
GT (1) GT200400116A (es)
MX (1) MXPA05012840A (es)
NL (1) NL1026329C2 (es)
PA (1) PA8604301A1 (es)
PE (1) PE20050628A1 (es)
TW (1) TW200524603A (es)
UY (1) UY28339A1 (es)
WO (1) WO2004108676A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2281813A1 (en) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
DK2035004T3 (en) * 2006-06-09 2013-01-02 Parion Sciences Inc Phenylsubstituerede pyrazinoylguanidin-natriumkanalblokkere med beta-agonistaktivitet
EP2077262A4 (en) 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
DE102008049675A1 (de) 2008-09-30 2010-04-01 Markus Dr. Heinrich Verfahren zur Herstellung von 3-Aminobiphenylen
PL2379507T3 (pl) 2008-12-30 2014-03-31 Pulmagen Therapeutics Inflammation Ltd Związki sulfonamidu do leczenia zaburzeń układu oddechowego
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6404944B2 (ja) 2014-04-24 2018-10-17 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
WO1996035671A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
ATE280167T1 (de) * 1999-07-23 2004-11-15 Pfizer Prod Inc Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0217225D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
BR0315234A (pt) * 2002-10-11 2005-08-23 Pfizer Derivados de indol como agonistas beta-2

Also Published As

Publication number Publication date
GT200400116A (es) 2005-03-03
TW200524603A (en) 2005-08-01
BRPI0410946A (pt) 2006-06-27
PE20050628A1 (es) 2005-08-30
WO2004108676A1 (en) 2004-12-16
DE602004008773D1 (de) 2007-10-18
UY28339A1 (es) 2005-01-31
ES2291882T3 (es) 2008-03-01
EP1633715B1 (en) 2007-09-05
MXPA05012840A (es) 2006-02-13
GB0312832D0 (en) 2003-07-09
DE602004008773T2 (de) 2008-01-10
ATE372321T1 (de) 2007-09-15
JP2006526613A (ja) 2006-11-24
EP1633715A1 (en) 2006-03-15
AR044475A1 (es) 2005-09-14
CA2527788A1 (en) 2004-12-16
NL1026329A1 (nl) 2004-12-07
CL2004001366A1 (es) 2005-05-06
NL1026329C2 (nl) 2005-07-26

Similar Documents

Publication Publication Date Title
PA8604301A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28724A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
PA8632801A1 (es) Derivados de tetrahidronaftiridina
NI200300025A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
UY28819A1 (es) Derivados de formamida para el tratamiento de enfermedades
PA8627101A1 (es) Compuestos para el tratamiento de enfermedades
DOP2004000921A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
DOP2005000043A (es) Compuestos para el tratamiento de enfermedades
PA8626401A1 (es) Compuestos útiles para el tratamiento de enfermedades
CR9838A (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2004000902A (es) Compuestos utiles para el tratamiento de enfermedades
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2005000037A (es) Compuestos utiles para el tratamiento de enfermedades
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades
CR8514A (es) Derivados de sulfonamida para el tratamiento de enfermedades
CU23661B7 (es) Derivados de formamida para el tratamiento de enfermedades
DOP2003000583A (es) Derivados de nicotinamida utiles como inhibidores de pde4
CU23532B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades